Pharma, Biotech and Generics Industry News | The Pharmaletter
Dec 6, 2024 · Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
Oblenio Bio | The Pharmaletter
Nov 7, 2024 · The company was launched by Aditum Bio in November 2024. Oblenio Bio was formed in conjunction with an exclusive option and license agreement with launched by Aditum Bio to develop LBL-051, a novel tri-specific T-cell engager developed using …
Trump vs Harris—who's on Big Pharma's side? | Pharmaceutical
Sep 22, 2024 · In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which ...
Analyst sees $66 billion precision medicine growth
Dec 5, 2024 · Technavio projects the global precision medicine market to grow by $66 billion from 2024 to 2028, driven by rising chronic diseases and AI integration in drug development. North America leads adoption, with key players like AbbVie, Amgen, AstraZeneca expanding targeted therapies in oncology and other disease areas.
Adcendo completes oversubscribed $135 million financing
Nov 25, 2024 · Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. The proceeds will be used to advance, broaden, and accelerate the development of the company’s first-in-class antibody-drug conjugate (ADC) pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs.
Novo Nordisk’s obesity newcomer monlunabant heads into Phase …
Sep 20, 2024 · Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo. Mild to moderate side effects were reported. A Phase IIb trial is planned for 2025
Novo Nordisk settles patent lawsuit over Ozempic
Oct 8, 2024 · Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US patent lawsuit over diabetes drug Ozempic (semaglutide). The lawsuit aimed to protect Ozempic’s market exclusivity until 2032. Mylan and Natco Pharma are developing a generic version, with exclusivity for six months after approval.
Atopia Therapeutics | Biotechnology - The Pharmaletter
Atopia's lead compound, ATP-R13, is designed as an oral first-line preventive and therapeutic treatment against asthma, eczema, food allergies, and related type-II atopic diseases.
Kailera Therapeutics | The Pharmaletter
Oct 1, 2024 · Kailera launched in October 2024 with a $400 million Series A financing co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital.
Alnylam Pharmaceuticals News | The Pharmaletter
Dec 9, 2024 · US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients …